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gon plasma 4.9 log 10 CFU/cm 2 , argon with admixed oxygen 
3 log 10 CFU/cm 2 , and with increased gas humidity 2.7 log 10 
CFU/cm 2 after 300 s) compared to CHG. In conclusion, SBD 
plasma is suitable as an alternative to CHG for inactivation of 
 Pseudomonas aeruginosa embedded in biofilm. Further de-
velopment of SBD plasma sources and research on the role 
of carrier gases and humidity may allow their clinical applica-
tion for wound management in the future. 
 © 2014 S. Karger AG, Basel 
 Introduction 
 Bacterial biofilms are described as attached bacteria on 
surfaces embedded in a matrix composed of self-pro-
duced substances, mainly polysaccharides, organic mate-
rial from the immediate environment and water  [1, 2] .
 Bacterial biofilm has been shown to play a role in de-
layed wound healing  [3–6] . Pseudomonas aeruginosa is one 
of the most important biofilm-forming species in chronic 
wounds  [7] . This organism, however, is difficult to eradi-
cate as it is protected against antimicrobial compounds by 
its biofilm, while at the same time it produces a number of 
enzymes, e.g. matrix metalloproteinases or toxins such as 
exotoxin A, which inhibit wound healing  [8, 9] .
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 Abstract 
 Because of its antimicrobial properties, nonthermal plasma 
could serve as an alternative to chemical antisepsis in wound 
treatment. Therefore, this study investigated the inactiva-
tion of biofilm-embedded  Pseudomonas aeruginosa SG81 by 
a surface barrier-discharged (SBD) plasma for 30, 60, 150 and 
300 s. In order to optimize the efficacy of the plasma, differ-
ent carrier gases (argon, argon admixed with 1% oxygen, 
and argon with increased humidity up to approx. 80%) were 
tested and compared against 0.1% chlorhexidine digluco-
nate (CHG) exposure for 600 s. The antimicrobial efficacy was 
determined by calculating the difference between the num-
bers of colony-forming units (CFU) of treated and untreated 
biofilms. Living bacteria were distinguished from dead by 
fluorescent staining and confocal laser scanning microsco-
py. Both SBD plasmas and CHG showed significant antimi-
crobial effects compared to the untreated control. However, 
plasma treatment led to a higher antimicrobial reduction (ar-
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 While mechanical debridement is the most effective 
measure for removing biofilm, topical antimicrobial 
compounds are also used to control and eradicate micro-
organisms inhabiting biofilms  [10, 11] . Combining phys-
ical and antimicrobial measures to remove biofilm and to 
kill off embedded microorganisms would be of added val-
ue in wound management  [12, 13] .
 The antimicrobial effect of plasma is mainly based on 
its reactive oxygen species (ROS), reactive nitrogen spe-
cies and UV radiation  [14–16] . While the basic principles 
of biological plasma effects have been studied extensively 
in recent years, data on optimal parameters for indepen-
dent variables (e.g. type of source, exposure time, gas 
mixture) differ between different application forms. 
However, determining the optimal adjustment of param-
eters from the experimental setups is crucial for develop-
ing clinical applications for future clinical use.
 The present study investigated the antimicrobial effi-
cacy of a nonthermal atmospheric pressure argon (Ar) 
plasma generated by a surface barrier-discharged (SBD) 
plasma source with different modifications (exposure 
time, gas mixtures) on in vitro biofilms of  P. aeruginosa 
in comparison to chlorhexidine digluconate (CHG). 
CHG is used in dentistry and represents the gold standard 
to inhibit plaque formation  [17] ; it is also used on wounds 
for wound antisepsis  [18–20] . Hence, CHG was chosen to 
serve as the positive control and additionally as a control 
of biofilm stability (susceptibility to antimicrobial treat-
ment).
 Because the plasma source used in this study also emits 
UV light, a risk assessment of UV irradiation on skin was 
conducted by measuring UV emission.
 Materials and Methods 
 Characteristics of the Plasma Source 
 The SBD plasma source (Neoplas GmbH, Greifswald, Germa-
ny) was developed by the Leibniz Institute for Plasma Science and 
Technology (INP), Greifswald, Germany. The plasma source 
works with sinus 30 kHz at U pp = 4 kV in a burst mode (250 ms 
on-time, 750 ms off-time) and covers an active discharge surface 
of 11 cm 2 . The electrical power was adjusted to 1.3 W, determined 
using a Lissajous curve (error limits: 10–20%)  [21, 22] , resulting in 
a surface power of 118 mW/cm 2 . A metal electrode was grounded 
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 Fig. 1. Experimental setup of the SBD plasma source.  a SBD plasma 
source fixed in casing for action.  b Bottom of the SBD plasma 
source in action.  c Plasma treatment of biofilm-covered disks.
 d Schematic depiction of SBD plasma source (cross-section). 
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for safety and connected to 7 black silicone-encased wires (thick-
ness: 0.6 mm each) serving as the dielectric barrier electrode. Con-
struction and experimental setup of the SBD plasma source are 
depicted in  figure 1 .
 The construction of this SBD electrode is applicable to different 
sizes and shapes; hence, the surfaces can be custom treated as the 
application demands, making it highly suitable for real-life appli-
cations  [23] . Additionally, the SBD electrode avoids direct dis-
charges to the substrate while always operating at room tempera-
ture near the electrodes  [24] . These physical properties make this 
SBD suitable for use as a tissue-tolerable plasma source.
 UV Radiation Measurement of the Plasmas 
 For all application modes, the exposure to UV radiation in the 
range of 180–400 nm was measured in microwatts per square cen-
timeter at a constant distance of 2 mm using spectrometry (Avantes 
AvaSpec-3648, Apeldoorn, The Netherlands). The area under the 
curve of the graph was calculated. The UV radiation exposure was 
determined in millijoules per square centimeter in accordance 
with ICNIRP guidelines (guidelines on limits of exposure to UV 
radiation of wavelengths between 180 and 400 nm)  [25] . The ery-
thema risk was determined in accordance with the Scientific Com-
mittee on Consumer Products report  [26] . 
 Cultivation and Evaluation of Experimental Biofilms 
 For the preparation and formation of a reproducible biofilm, 
the strongly biofilm-forming  P. aeruginosa strain SG81 was used, 
as described earlier  [19, 27, 28] . The biofilms were cultivated on 
polycarbonate disks (diameter 13 mm, height 3 mm; Arthur 
Krueger KG, Barsbüttel, Germany) submerged in an artificial 
wound-like fluid consisting of minimal essential medium and 10% 
fetal bovine serum (Gibco-Invitrogen, Germany)  [29] serving as 
growth medium. The batch medium had a final concentration of 
10 8 colony-forming units (CFU)/ml. Sterile disks were positioned 
in 24-well microplates (Sarstedt AG & Co., Nümbrecht, Germa-
ny), covered with 0.8 ml batch medium, and incubated aerobically 
for 72 h in an agitator system (Polymax, Heidolph, Germany) at 
150 revolutions per minute (r.p.m.). Medium was replaced after 24 
and 48 h with sterile artificial wound medium, and the polycarbon-
ate disks were turned inside the respective wells. The incubation 
temperature was set to 37   °   C for the first 48 h, and 23   °   C for the 
following 24 h.
 The final disks covered with biofilm were washed with phos-
phate-buffered saline solution to remove unattached bacteria and 
were transferred to sterile microplates for the subsequent experi-
ments. 
 Finally, after the experiments, all disks were placed in micro-
plates, were filled with 1 ml of physiological saline solution per 
well, and treated by ultrasound (130 W, Branson 2510 Ultrasonic 
Cleaner, Emerson Technologies GmbH & Co. OHG, Dietzenbach, 
Germany) for 20 min to disperse the biofilms. Planktonic bacteria 
were determined by the spread plate method on tryptic soy agar 
(CASO-Agar, Carl Roth GmbH & Co. KG, Karlsruhe, Germany).
 Plasma Experiments on Biofilms 
 Biofilm-covered carrier disks were positioned on a flat metallic 
grate, in order to keep the contact area at a minimum, and placed 
in a petri dish. The SBD plasma source was positioned above the 
disks and immobilized by fixing at 3 points ( fig. 1 ). In each exper-
iment, the distance between the dielectric wire and the surface of 
the disks was adjusted to 2 mm with the support of the casing of 
the plasma source. A gas flow of 5 standard liters/min was applied 
through small holes along the black wires in the metal electrode 
and was controlled by a mass flow controller (MKS Instruments, 
Munich, Germany). Ambient air exchange was allowed through 
the gap between the electrode and the edge of the petri dish.
 Plasma or gas control was applied using Ar (99.995% pure), Ar 
admixed with 1 vol% oxygen (Ar + O 2 , O 2 99.5% pure), or Ar with 
80% relative gas humidity (Ar + H 2 O). The water content of the 
pure Ar and O 2 gas was <3 ppm/mol. In all assays, both sides of the 
disks were treated for 30, 60, 150 or 300 s. In order to increase the 
relative humidity to 80 ± 4% (at 21   °   C) for Ar, the gas flow was 
piped through a bottle containing distilled water. The resulting 
humidity was measured using a hygrometer (testo 400, Lenzkirch, 
Germany). 
 Antimicrobial Treatment of Biofilms Using CHG as Antiseptic 
Reference  
 For treatment with CHG instead of plasma, biofilm-covered 
carrier disks were also placed in microplate wells, filled with 0.9 ml 
of a 0.1% (w/v) CHG solution (Fagron GmbH & Co. KG, Barsbüt-
tel, Germany) and incubated for 600 s. Antiseptic activity was neu-
tralized by replacing CHG with 1 ml of inactivation solution for 
600 s (40 g/l Tween 80, 30 g/l saponin, 4 g/l lecithin, 10 g/l sodium 
dodecyl sulfate, 1 g/l sodium thioglycolate; Serva ,  Heidelberg ,  Ger-
many). The efficacy of the neutralizer was validated following the 
Standard European Norm DIN EN 1040  [30] .
 Staining of Biofilm and Microscopic Evaluation 
 Two fluorescent nucleic acid stains, Syto ® 9 (Syto9) and pro-
pidium iodide (Live/Dead-BacLight, Invitrogen GmbH, Darm-
stadt, Germany), were used for discrimination of intact (stained 
with Syto9, green signals) and membrane-damaged (stained with 
propidium iodide, red signals) bacteria  [31] . The treated experi-
mental and untreated control biofilm disks were transferred into 
24-well microplates (Techno Plastic Products AG, Trasadingen, 
Switzerland) and covered with 0.5 ml of staining solution (6.7 μ M 
of Syto9 and 5 μ M of propidium iodide) for 30 min at 80 rpm on 
an agitator system (IKA ® KS 130 basic, Staufen, Germany) in the 
dark. The staining solution was removed, and the disks were 
washed with 1 ml PBS. Finally, the stained biofilm disks were trans-
ferred into a new 24-well microplate. A confocal laser scanning 
microscope (Zeiss CLSM510 Exciter, Carl Zeiss MicroImaging 
GmbH, Jena, Germany) equipped with a ×10 objective (Zeiss EC 
Plan-Neofluar ×10/0.3) was used for imaging.
 Statistical Analysis 
 CFU counts per square centimeter were transformed to log 10 
(CFU) per square centimeter. For each sample the colony reduc-
tion factor (RF) was calculated by subtracting the log 10 (CFU) per 
square centimeter value of the treated sample from the log 10 (CFU) 
per square centimeter of the mean value of the untreated control. 
For each condition, means and standard deviations were calcu-
lated based on the RFs. Statistical differences between RFs of dif-
ferent treatment modalities and times were analyzed with the 
Kruskal-Wallis test, followed by a Mann-Whitney U test using the 
statistical analysis software SAS ® Enterprise Guide ® 4.1 (SAS In-
stitute GmbH, Heidelberg, Germany).
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 Results 
 Regardless of the respective tested condition, all plas-
ma treatments resulted in a measurable microbial reduc-
tion ranging between 0.97 log 10 CFU/cm 2 (Ar + H 2 O plas-
ma) and 4.88 log 10 CFU/cm 2 (Ar plasma), compared to 
untreated controls (p < 0.009). The RFs increased with 
longer and decreased with shorter treatment time, show-
ing a strong correlation with the plasma exposure time.
 The antimicrobial efficacy of CHG (1.4 log 10 CFU/
cm 2 ) after 600 s was reached by Ar plasma within 60 s and 
by Ar + O 2 plasma within 30 s. Ar + H 2 O plasma was less 
effective, reaching the antimicrobial reduction efficacy of 
CHG after 150 s. For longer treatment times, reductions 
were significantly superior (p < 0.014) to CHG treatment 
( table 1 ).
 Plasma control with pure Ar gas flow also resulted in 
significant bacterial reduction (maximum reduction was 
1.5 log 10 for Ar gas, 2 log 10 for Ar + O 2 gas and 0.9–1.3 
log 10 for Ar + H 2 O gas) compared to the untreated con-
trol, yet the RFs were smaller and showed no correlating 
time dependency. The antimicrobial efficacy shown by 
Ar + H 2 O gas control was always low, with an RF in the 
range of approximately 1 log 10 CFU/cm 2 . The difference 
from the negative control was not statistically significant 
(p = 0.36). However, plasma was significantly more effec-
tive for the carrier gas Ar after 60–300 s and for Ar + H 2 O 
after 300 s of exposure compared to the gas treatment 
Table 1.  Summary of results
Treatment mode Ar Ar + O2  Ar + H2O p
n RF ± SD 95% CI limits n RF ± SD 95% CI limits n RF ± SD 95% CI limits
lower upper lower upper lower upper
Plasma
30 s 22 1.15 ± 0.99a 0.72 1.59 14 1.66 ± 1.20c 0.97 2.36 6 0.97 ± 0.37 0.58 1.36 0.2242
60 s 21 1.63 ± 0.67b, c 1.32 1.94 13 2.19 ± 1.28c 1.42 2.97 12 1.19 ± 0.86 0.64 1.73 0.0438
150 s 21 2.45 ± 1.03a, b 1.98 2.91 14 2.62 ± 0.95a, b 2.07 3.17 6 1.55 ± 0.93 0.58 2.52 0.0976
300 s 14 4.88 ± 2.21a–c 3.60 6.15 12 2.97 ± 1.64a 1.93 4.01 6 2.65 ± 1.21a, b 1.38 3.92 0.0666
p 0.0001 0.0355 0.0313 0.0001
Gas
30 s 6 0.66 ± 0.50a 0.13 1.18 7 1.94 ± 1.19 0.84 3.05 6 0.85 ± 0.65 0.17 1.53 0.0784
60 s 6 0.62 ± 0.26a 0.35 0.88 7 1.41 ± 0.53 0.97 1.85 6 0.56 ± 0.56 –0.03 1.14 0.0135
150 s 14 1.11 ± 0.83 0.63 1.59 12 0.79 ± 0.43 0.52 1.07 6 1.28 ± 1.10 0.12 2.43 0.6751
300 s 11 1.52 ± 0.80 0.98 2.05 8 1.97 ± 1.31 0.87 3.06 6 0.47 ± 0.30 0.16 0.79 0.0052
p 0.0153 0.018 0.3589 0.4598
CHG 0.1% 22 1.41 ± 0.73 1.08 1.73
Control 36 0.00 ± 0.340 –0.19 0.06
p 0.0001 0.0001 0.0001 0.0001
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 Fig. 2. Spectrometric graph of irradiance by generated Ar, Ar with 
1% O 2 admixture and Ar with 80% gas humidity plasma during 
300 s of exposure time between 180 and 400 nm. 
Number of samples (n), RF expressed as log10 CFU per square centimeter 
± standard deviation (SD), lower and upper 95% confidence intervals (CI) 
after Ar plasma, Ar + O2 plasma and Ar + H2O plasma treatment for 30 – 
300 s treatment time and for 300 s treatment time of respective gas controls, 
0.1% CHG after 600 s exposure time and untreated control of P. aeruginosa 
SG81 biofilms; p values of omnibus tests (Kruskal-Wallis) and two-sample 
tests (Whitney U); statistical significance: α = 0.05. a p ≤ 0.05: significantly 
different from CHG; b p ≤ 0.05: significantly different from the respective gas 
control; c p ≤ 0.05: significantly different from the respective Ar + H2O plas-
ma treatment time.
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alone (p < 0.004). The efficacy of Ar + O 2 plasma after
60 s of exposure was higher than the respective gas treat-
ment serving as control. However, the differences of the 
RFs were not statistically significant.
 Increasing the relative humidity of the carrier gas did 
not lead to greater antimicrobial efficacy; on the contrary, 
the RF of Ar + H 2 O plasma was significantly lower than 
that of Ar plasma after 300 s (p = 0.0408).
 The maximum UV irradiation from the plasma source 
was 14.6 μW/cm 2 , which was measured during the use of 
pure Ar plasma. This UV value corresponded to a UV ra-
diation exposure of 0.32 mJ/cm 2 during 300 s of treat-
a b
c
Fig. 3. Top view of orthogonal section of biofilms. x-, y-, z-axis 
(red, green, blue lines). Live/dead staining of bacterial nucleic acid 
in biofilms (CLSM510 Exciter, objective ‘Plan-Neofluar’ 10×/0.3, 
Zeiss, Jena). Living cells stain green (Syto9 ® ) and dead cells stain 
red (propidium iodide); yellow is the overlap of green and red ar-
eas, showing the effect of Ar plasma and CHG on biofilms of  P. 
aeruginosa SG81 grown on polycarbonate disks.  a Untreated bio-
film.  b After 300 s of Ar plasma treatment.  c After 600 s of 0.1% 
CHG treatment. 
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ment. The other gas variations showed lower UV radia-
tion exposures of 0.07 mJ/cm 2 by Ar + O 2 plasma, and 
0.03 mJ/cm 2 by Ar + H 2 O plasma during 300 s of treat-
ment. The highest measured erythema dose was 0.0032 
W/m 2 for Ar plasma. A spectrometric graph of the UV 
irradiance by Ar, Ar + O 2 and Ar + H 2 O plasma is shown 
in  figure 2 .
 The biofilm thickness of 24.5–30.6 μm remained un-
changed after treatment for nondetached, stainable bio-
films.  Figure 3 shows the fluorescence images of plasma- 
and CHG-treated (positive control) as well as untreated 
negative control biofilms. Image analysis of biofilms after 
plasma treatment showed a smaller area of fluorescence 
with irregularly distributed red signals in comparison to 
the other samples. After CHG treatment, the distribution 
of red signals was notably superficial as opposed to deep-
er, greener signals before CHG treatment. 
 Discussion 
 Treatment of bacterial biofilms by application of phys-
ical plasma is of special interest, because this could be an 
alternative method to the application of chemical antimi-
crobials. It offers new options for inactivating microor-
ganisms inhabiting biofilms on prosthetic material or 
chronic surface tissue infections, e.g. in chronic wounds. 
 To ascertain the safety of the SBD-generated plasma 
for possible applications on human skin, we quantified 
the UV emission. Other than solid inanimate surfaces, 
human cells in wounds may be damaged by UV irradia-
tion, particularly in the wavelength range of 180–400 nm 
 [25, 32–34] . At high doses, UV radiation may not only 
cause cell damage and lead to apoptosis but may also in-
duce cancer  [35] . Depending on the gas or gas mixture 
used, the measurements showed that the UV radiation 
emitted by the SBD plasmas ranged between 0.03 mJ/cm 2 
(Ar + H 2 O plasma) and 0.32 mJ/cm 2 (1.06 μW/cm 2 ; Ar 
plasma) for 300 s of application time at a distance of 2 mm 
(comparable to distance during biofilm treatment). In 
humans, the maximum accepted UV radiant exposure 
limit for intact skin over 300 s is 3 mJ/cm 2 (10 μW/cm 2 ), 
as stated in the ICNIRP guidelines  [25] . Additionally, the 
weighted total erythema irradiance of 0.0032 W/cm 2 is 
clearly below the erythema risk threshold (0.3 W/m 2 ), in 
accordance with the Scientific Committee on Consumer 
Products report  [26] . The UV and erythema irradiance 
determined was lower than the reported UV exposure 
produced by the Ar plasma source which was used to treat 
chronic wounds  [36] . These results indicate that the UV 
irradiation of the SBD plasma is negligibly low, which is 
one important prerequisite for the use of plasma in hu-
man wounds.
 The effect of various gas admixtures for optimized an-
timicrobial efficacy in biofilms was investigated in this 
study. Up to now, no accepted standard for testing anti-
microbial compounds against microbial biofilms has 
been defined. Therefore, the described assay was devel-
oped, which proved reliable and easy to use for the re-
search questions posed here.  The untreated controls 
showed means of 7.14 ± 0.8 log 10 CFU/cm 2 and were suit-
able for calculating the RFs for statistical analyses (in ac-
cordance with DIN EN 1040  [30] ). These high colony 
counts were achievable by using a distinct  P. aeruginosa 
test strain  [37] . Using this strain, pretests showed a stron-
ger biofilm structure if the incubation temperature was 
decreased to room conditions for the last 24 h of incuba-
tion while more intense bacterial growth occurred during 
the first 48 h at 37  °  C. An artificial wound fluid was used 
to simulate a wound-like environment during biofilm 
culture. Polycarbonate disks were used as the adhesion 
surface. This material is suitable for the adherence and 
biofilm formation of  P. aeruginosa  [38] .
 Chlorhexidine is used in topical antimicrobial wound 
dressings and is also regarded as the gold standard to 
eradicate dental plaque and consequently inactivate and 
prevent biofilms  [39] . Therefore, CHG was used in the 
present experiments as the positive control. It demon-
strated a significant bacterial reduction of 1.4 log 10 CFU/
cm 2 after 600 s of application (p < 0.0001). It was expect-
ed that any plasma treatment must at least demonstrate 
antimicrobial reduction efficacy equal to or significantly 
higher than CHG compared to the untreated negative 
control. 
 In our experiments, the efficacy of Ar plasma and of
Ar + O 2 plasma after 150 s and of Ar + H 2 O plasma after 
300 s was higher than the antimicrobial efficacy of CHG. 
The RFs achieved by the various plasma conditions are in 
agreement with similar previously published studies  [19, 
40] .
 Ar showed a strong antimicrobial effect, which in-
creased steadily with increasing plasma exposure time 
from approximately 1 to 4.9 log 10 (CFU)/cm 2 . This reduc-
tion rate is comparable to the antimicrobial efficacy of a 
helium  [41] or an Ar  [42] plasma jet against biofilms of
 P. aeruginosa . Yet not only Ar, but also the Ar gas flow 
showed an antimicrobial effect, which was also reported 
elsewhere for an Ar plasma jet on biofilms  [42] . This ob-
servation may be explained by a simple drying effect of 
the biofilm by the gas flow itself, since the effect was sig-
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nificantly reduced when humidity was added in the ex-
periments using Ar + H 2 O gas. However, the Ar plasma 
effect was significantly higher than the pure gas effect 
alone for 60–300 s of exposure time.
 The SBD plasma source used for this study allowed 
admixing O 2 to the Ar gas or enriching it with distilled 
water. By adding O 2 or increasing humidity, an increased 
concentration of ROS (e.g. O, O2–, OH, H 2 O 2 ,  1 O 2 , O 3 ) was 
expected  [43, 44] . Especially the electrons of Ar plasma 
have enough energy to dissociate O–H bonds of water, so 
the gas humidity may increase the concentration of OH 
radicals  [45] . ROS are essentially downstream products of 
the plasma due to its reaction with room air or with water 
on the substrate and result in increased antimicrobial ef-
ficacy  [45, 46] .
 Surprisingly, the increased humidity decreased the 
plasma’s antimicrobial efficacy against  P. aeruginosa in 
treated biofilms. Other authors reported an increased 
antimicrobial effect with additional gas humidification 
 [47–49] . Hähnel et al.  [47] observed an improved effect 
for an air plasma by increasing the relative air humidity 
up to 70% against  Bacillus atrophaeus spores. The au-
thors discussed that especially hydroxyl radicals have an 
erosive effect on cell surfaces. Indeed, it is known that a 
very small amount of moisture on the microbial target is 
needed for inactivation with species such as  · OH or
H 2 O 2  [48–50] . This could explain why an increased ef-
fect was observed when humidified gas was applied on 
dry spores. While in the experiments on  B. atrophaeus 
spores  [47] only the amount of water needed for the plas-
ma decontamination process was used, the biofilm in 
our experiments already contained the water necessary 
for antimicrobial effects, leaving no chance for enhance-
ment due to humidification. Dobrynin et al.  [48] ob-
served an enhanced antimicrobial efficacy by carrier gas 
humidification (bubbled through distilled water) only if 
additional O 2 was admixed. Here, the relative gas hu-
midity could be the same as in the present study and our 
plasma source worked in ambient air, which could pro-
vide the additional O 2 . Srivastava and Wang  [49] ob-
served an enhanced effect with increased humidity alone 
in Ar plasma, yet with a lower relative water content than 
used in our study. According to those authors, an H 2 O:Ar 
ratio of 1.5% was optimal for acquiring high amounts of 
OH radicals in plasma effluvium. The increase in anti-
microbial effectiveness seems to be very small, because 
increasing the relative humidity to 20–80% did not sig-
nificantly change the efficacy of air plasma  [51] . Conse-
quently, the relative humidity of 80% in Ar could have 
been set too high.
 All groups of authors used different plasma devices, 
carrier gases, or application systems, but none focussed 
on the determination of the plasma effect against biofilm 
bacteria or worked in ambient conditions in the way de-
scribed in the present study, making direct comparison 
difficult. Finally, the high gas humidity of 80% in Ar could 
have led to a loss of electron density for plasma generation 
 [45] that may have inhibited important antimicrobial 
components, explaining why the antimicrobial efficacy of 
Ar + H 2 O plasma was lower than that of Ar plasma. 
Therefore, a higher energy input for plasma generation or 
lower Ar humidity may be able to increase the efficacy of 
Ar + H 2 O plasma. Another explanation could be a shift 
of different ROS generated to H 2 O 2 by the added H 2 O 
vapor  [52] , since  P. aeruginosa can neutralize these per-
oxides by producing catalases  [53] , showing increased re-
sistance against H 2 O 2 in biofilms  [54] . Further investiga-
tions are necessary to understand this phenomenon, be-
cause the plasma chemistry of humidified air plasma is 
very different from humidified Ar plasma, and from hu-
midified Ar plasma working in ambient conditions. The 
ambient conditions for plasma treatment were chosen to 
simulate the clinical conditions of wound treatment on 
patients.
 Correlations between the antimicrobial effects of plas-
ma and biofilm water content should be a topic of future 
studies.
 The results of this study demonstrated that the addi-
tion of 1% O 2 to Ar accelerated the onset of the antimi-
crobial effect, but with longer treatment time, the efficacy 
decreased again, particularly in comparison to Ar plasma 
alone. Comparable results were shown by the use of an Ar 
plasma jet  [42] . Possibly, the admixture of 1% O 2 quench-
es the excited Ar species  [55] and inhibits secondary plas-
ma products which are important for potential antimi-
crobial effects against  P. aeruginosa . Otherwise, on scan-
ning electron images, some other authors have shown cell 
detritus after plasma treatment  [40, 56, 57] . It may well be 
that an increased O 2 concentration accelerates microbial 
cell damage, which may result in a plasma shadow effect 
by accumulated cell detritus. This could explain why the 
antimicrobial efficacy of Ar + O 2 plasma increased very 
slowly with longer application times. 
 In order to take advantage of possible ROS by O 2 ad-
mixtures for treatment of  P. aeruginosa in biofilms, fur-
ther studies on optimizing the Ar:O 2 ratio in plasma are 
required.
 The antimicrobial effect after treatment with Ar + O 2 
gas was higher than after Ar gas treatment and cannot be 
explained only by the drying effect of the biofilm. It is 
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known that relatively low O 2 concentrations dominate 
within  P. aeruginosa biofilms (vs. on their surface)  [58, 
59] and that pure O 2 can diffuse more easily through the 
biofilm matrix than can air, for example  [58] . The ini-
tially O 2 -poor status of biofilm to which O 2 was added 
could explain the effect of the rapid onset within 30 s, the 
slow progress with longer exposure to Ar + O 2 plasma, 
and the high antimicrobial effect of Ar + O 2 gas flow with 
increased O 2 stress of  P. aeruginosa . The difference be-
tween Ar + O 2 gas and Ar + O 2 plasma is only 1 log 10 af-
ter 300 s of exposure and was not significant. In com-
parison to the other treatment times, the low effect of 0.8 
log 10 CFU/cm 2 at 150 s by Ar + O 2 gas is currently inex-
plicable, because the procedure was constant for all sam-
ples. 
 To avoid a dominant gas flow effect for efficient anti-
microbial reduction of microorganisms in biofilms, treat-
ment with Ar or Ar + H 2 O plasma is recommended.
 The fluorescence images showed darker regions after 
plasma treatment. This could be a result of reduced ad-
herence of biofilm, or reduced staining may have been 
due to loss of DNA caused by the plasma effect and the 
additional washing procedure. Furthermore, the distri-
bution of live and dead  P. aeruginosa cells was different 
between plasma- and CHG-treated biofilms. The z-axis 
of the images after CHG treatment shows more red sig-
nals (dead bacteria) in the surface regions of the biofilm 
structure and green signals (live bacteria) in deeper re-
gions, while signals were distributed irregularly after 
300  s of Ar plasma treatment. This indicates that the 
 antimicrobial efficacy of Ar plasma is homogeneously 
distributed through the biofilm structure, while CHG did 
not reach deeper layers of the biofilm. A homogeneously 
distributed effect of plasma in deeper regions of the bio-
films was also shown by other authors  [13, 41, 60] .
 While the assay allowed investigation of plasma effects 
under standardized conditions, this experimental biofilm 
does not correspond to complex multispecies biofilms 
found in vivo as in chronic infected wounds  [61] . Addi-
tionally, the experimental model used in this study does 
not correspond to the complex wound conditions found 
in chronic wounds. Finally, such well-defined physical 
conditions during plasma treatment as were present in 
our experimental tests are not found in the clinical set-
ting, since differences in the distance of the plasma source 
to the surface, in room temperature, and in humidity con-
ditions are to be expected. 
 Conclusion 
 The results of this study demonstrate that the high an-
timicrobial efficacy of the SBD plasma source used 
against  P. aeruginosa embedded in biofilm exceeds that 
of CHG applied for 600 s. SBD plasma may be suitable as 
an alternative or supplemental treatment to chemical an-
tiseptics in the treatment of biofilm-associated wound 
infections. These effects, however, depend on chemical 
and physical factors, such as the plasma gas condition, 
but also the physical condition of the surrounding air. 
The admixture of O 2 to Ar for plasma generation led to 
an increased antimicrobial effect, albeit only for short 
treatment times. Concurrently, an increased humidity of 
Ar of approximately 80% to Ar for plasma generation 
reduced the plasma’s antimicrobial effect in the presence 
of biofilm. Further basic research on SBD plasma sourc-
es and on the role of carrier gases and humidity is needed 
to better understand the complex plasma physics in clin-
ical practice.
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